How do you approach initial anticoagulant selection in hemodynamically stable hospitalized patients with newly diagnosed pulmonary embolism?
The recent AHA/ACC guideline updates favor low‑molecular‑weight heparin over unfractionated heparin for initial parenteral anticoagulation. Have you noticed shifts in your approach as newer PE risk‑stratification frameworks gain traction, or does anticoagulant choice remain largely unchanged?
1 Answer
Mednet MemberInvited Expert
Hospital Medicine · University of California San Diego
Answered on
Low-molecular-weight heparin demonstrates the greatest benefit in patients with cancer-associated pulmonary embolism, intermediate-risk PE, and those requiring outpatient management. While LMWH shows superior efficacy and safety compared to unfractionated heparin across most patient populations, cer...
Join for free or sign in to see the full answer